Skip to main content
All articles

Site Operations

The retention work between visits: how to price budget amendments for long-term cardiovascular trials

By Julio G. Martinez-Clark Published November 11, 2026 Updated November 11, 2026 6 min read

Why the annual visit is not the whole job

A budget built around visits treats follow-up as a series of appointments. The protocol treats it as a continuous obligation. Between one annual visit and the next, the site still has to reach participants who move, change phone numbers, or stop answering. It has to document each contact attempt. It has to record vital status when a participant cannot attend. It has to answer queries about follow-up data long after the visit that generated the data has been paid.

None of that work appears on a schedule of assessments, so none of it appears in a per-visit rate. Early in a trial, when enrollment is active and visit revenue is flowing, a site can quietly carry the cost. Years later, in a long extension or a follow-up-only phase, visit revenue thins out while the retention obligation stays the same size. That moment is predictable, not a surprise. The better practice is to read the follow-up phase at negotiation, list the between-visit duties it creates, and notice that almost none of them are attached to a billable visit.

Price the population, not the calendar

The first correction is the unit of pricing. An amendment priced off the calendar — a flat annual amount for the study, regardless of how many participants remain in follow-up — drifts out of line in both directions. It overpays when the follow-up population has shrunk and underpays when the population is still large, and either error gives the sponsor a reason to question the line at the next negotiation.

Price the amendment to the active follow-up population instead. Define the population plainly: participants who have completed the treatment phase and remain in protocol-required follow-up, and who have not withdrawn consent, died, or completed their final follow-up obligation. Count that population on a stated date each year, agree the count with the sponsor's own records, and apply the annual amount to that count. The structure is illustrative — the point is the unit, not any particular figure, and no published benchmark will set the amount for your study. The amount has to come from your own record of what the work takes: contact attempts per participant, coordinator time per attempt, and oversight time on the data those attempts produce.

A population-based line also behaves honestly: as participants complete follow-up, the line falls.

Name the line for what the protocol requires

Sponsors push back on vague lines, and they are right to. A line called retention support or administrative follow-up invites a reviewer to treat it as overhead and cut it. The same work, named for the protocol duty it performs, reads differently.

Name the line for what the protocol requires. Where the protocol requires PI review of follow-up data, say so: PI review of follow-up data and safety oversight between visits is a definable duty, performed by a named person, on a recurring cycle. Where the work is participant contact, name the activity: documented contact attempts and vital-status ascertainment for participants in long-term follow-up. Each name points to a protocol section, a responsible role, and an output the sponsor can verify — a signed review, a contact log, a vital-status entry.

Reviewers fund obligations. They cut effort.

Log principal investigator time that a coordinator could have handled

The second record an amendment needs is a PI time log, and not only for the oversight the protocol requires. Log the PI hours spent on monitoring-visit items that a clinical research coordinator (CRC) could have resolved: routine data queries that needed a signature rather than a medical judgment, document corrections, administrative clarifications raised at monitoring visits and routed to the PI by default rather than by need.

Keep the log simple: date, study, item, time spent, and why it reached the PI. Internally, it shows which items should be redirected to the CRC with a clear escalation rule. Externally, it turns a fee request into a workload record. Presenting a log of PI hours already spent is much harder for a sponsor to dismiss than a rate negotiation, because the site is not forecasting — it is reporting.

Ask for that time as a separate line rather than folding it into the per-participant amount. Separate lines can be reviewed, adjusted, and renewed on their own evidence. Folded-in time disappears, and disappears permanently at the next amendment.

What to put in the amendment request

A complete request is short, because the records do the arguing. It should contain:

  • The follow-up population count, with the counting date, the definition used, and agreement with the sponsor's records.
  • The between-visit duties, each named for the protocol requirement it satisfies, with the responsible role for each duty.
  • The contact and vital-status workload, drawn from the site's own logs: attempts made, outcomes recorded, and time taken.
  • The PI time log, separating protocol-required oversight from monitoring-visit items a CRC could have resolved, with the request that oversight time be funded as its own line.
  • The proposed structure, stated plainly: an annual amount applied to the active follow-up population, reviewed when the population count is refreshed, with no invented benchmarks presented as market data.

Early closures are a data risk, not just a site problem

When long-term follow-up terms are unsustainable, sites close early, and the closure is usually described as a site problem. It is not. Every early closure in a long-term CV trial puts the sponsor's follow-up data at risk: participants who were reachable become unreachable, vital-status ascertainment stops, and years of follow-up effort end in incomplete records. The sponsor keeps the cost of the trial and loses part of the evidence the trial existed to produce.

That makes early closures evidence, and sites should use them that way — carefully, and without naming other sites or studies. The pattern is the argument: when follow-up work is unfunded, follow-up data is what fails. A sponsor is not choosing between paying and not paying. It is choosing between funding retention while the population is still reachable, and accepting the data loss that follows when sites can no longer carry it.

How this works in practice

At Amavita Research, our Miami cardiovascular trial site, we care for more than 18,000 active cardiology patients, and our record includes zero United States Food and Drug Administration (FDA) Form 483 findings. Long-term follow-up is where a site with a population like ours either protects a sponsor's data or quietly loses it, and the difference is rarely effort — it is whether the budget funds the work between visits. Price the amendment to the active population. Name each line for the protocol duty it performs. Log the PI time and present the log. That is how retention work stops being invisible, and how follow-up data survives to the end of a long trial.

Julio G. Martinez-Clark is chief executive officer of Amavita Research Services, a Miami cardiovascular trial site, and chief executive officer of bioaccess, a first-in-human contract research organization.

Next step

Sponsors: see what Amavita Research can run

Amavita Research is a Miami cardiovascular trial site with 18,000+ active cardiology patients and zero United States Food and Drug Administration (FDA) Form 483 findings. See our site capabilities or talk with our sponsor team.

By Julio G. Martinez-Clark · Last updated November 11, 2026. This article is site-operations education and is not medical advice or a regulatory recommendation.